“We're not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z
News Source
•Sat, 29 Aug 2026 17:36:47 +0000
📰 What Happened
Vijay Pande used to run a $4 billion health and biotech fund at the famous venture firm Andreessen Horowitz (a16z). Last June, he walked away to start a much smaller firm called VZVC with longtime investor Zach Werner. Instead of making dozens of bets a year, VZVC makes just a handful of careful ones.
The new firm has no associates and leans heavily on AI for daily work. Pande says he wants focus, not spread. He also talked about a big problem in AI-driven medicine: biological data cannot be scraped off the internet like text, so every company builds its own private dataset.
🔍 The Backstory
Pande was a Stanford chemistry professor, best known for building Folding@home. That project turned millions of home computers into one giant supercomputer for disease research. About twelve years ago, a16z decided to bet on healthcare and handed the whole field to him.
He grew that bet into a practice managing close to $4 billion, making him one of the biggest names in biotech investing. His move from giant fund to small firm is a notable shift in how investors think about the AI era.
🎯 Why It Matters
AI could speed up new medicines, but only if researchers can share data. If every company hides its data in a walled garden, progress slows down. This debate decides how fast we get cures and who gets access to them.
Vijay Pande used to run a $4 billion health and biotech fund at the famous venture firm Andreessen Horowitz (a16z). Last June, he walked away to start a much smaller firm called VZVC with longtime investor Zach Werner. Instead of making dozens of bets a year, VZVC makes just a handful of careful ones.
The new firm has no associates and leans heavily on AI for daily work. Pande says he wants focus, not spread. He also talked about a big problem in AI-driven medicine: biological data cannot be scraped off the internet like text, so every company builds its own private dataset.
Pande was a Stanford chemistry professor, best known for building Folding@home. That project turned millions of home computers into one giant supercomputer for disease research. About twelve years ago, a16z decided to bet on healthcare and handed the whole field to him.
He grew that bet into a practice managing close to $4 billion, making him one of the biggest names in biotech investing. His move from giant fund to small firm is a notable shift in how investors think about the AI era.
AI could speed up new medicines, but only if researchers can share data. If every company hides its data in a walled garden, progress slows down. This debate decides how fast we get cures and who gets access to them.